Rebus Holdings, Inc. financial data

Symbol
RBSH on OTC
Industry
Pharmaceutical Preparations
Location
2629 Townsgate Rd, Suite 215, Westlake Village, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Inspyr Therapeutics, Inc. (to 10/12/2021), GENSPERA INC (to 7/25/2016)
Latest financial report
10-Q - Q2 2023 - Aug 21, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.69 % -93.7%
Debt-to-equity -101 % +10.1%
Return On Equity -10.2 % +87.1%
Return On Assets 1.49K % +127%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.1M shares 0%
Common Stock, Shares, Outstanding 32.1M shares 0%
Entity Public Float 766K USD -79.2%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 32.1M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 161M shares +400%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 85K USD -85.7%
General and Administrative Expense 388K USD -25%
Operating Income (Loss) -473K USD +57.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 570K USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 570K USD -86.4%
Earnings Per Share, Basic 0.02 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5K USD -99.3%
Assets, Current 9K USD -96.6%
Assets 9K USD -96.6%
Accounts Payable, Current 1.66M USD -7.61%
Employee-related Liabilities, Current 1.33M USD 0%
Accrued Liabilities, Current 2.12M USD +3.36%
Liabilities, Current 5.62M USD -8.75%
Liabilities 5.62M USD -13.1%
Retained Earnings (Accumulated Deficit) -65.7M USD +0.86%
Stockholders' Equity Attributable to Parent -5.61M USD +9.56%
Liabilities and Equity 9K USD -96.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -124K USD +15.1%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 32.1M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -124K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5K USD -99.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 10.4M USD -14.3%
Deferred Tax Assets, Gross 10.4M USD -14.3%
Deferred Tax Assets, Operating Loss Carryforwards 9.53M USD +1.95%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares 0%
Additional Paid in Capital 60.1M USD +0.04%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%